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ABSTRACT 
Painful Diabetic Neuropathy (PDN) is one of the most common and annoying 
complications of diabetes mellitus. The pathogenesis of PDN is complex and still unclear. 
Recently it has become clear that nitric oxide (NO) and proinflammatory cytokines play 
an important role in the pathogenesis and maintenance of pain in PDN. Based on this 
phenomenon, this study was conducted to investigate whether the cytokine tumor 
necrosis factor-alpha (TNF-) and NO, in this case inducible Nitric Oxide Synthase 
(iNOS), play a role in PDN pathogenesis.  
 The study was carried in two steps. The first step was a cross sectional and the 
second step was a case-control study. The study was performed in 110 type-2 diabetic 
patients. The plasma TNF-  levels were determined by ELISA while the expression of 
TNF- and iNOS in mononuclear cells were analyzed immunohistochemically. 
Of 110 subjects, 59 patients suffered from Painful DN (case) and the remaining 
51 patients were Painless DN (control). Cross sectionally, plasma TNF- levels and 
immunoreactivity for iNOS and TNF- were higher in patients with more severe pain in 
the Visual Analog Scale (VAS). There were statistically significant differences   (p < 
0.05) between mild and severe pain in regard to TNF- level (15.24 pg/ml ± 5.42  vs. 
20.44 pg/ml ± 10.34 ); to iNOS immunoreactivity (9.72 % ± 8.61 vs. 15.6% ± 11.84); and 
to TNF- immunoreactivity (13.0 % ± 9. 48 vs. 20.44% ± 11.75).  
The case control study showed that TNF- had an odd ratio of 5.053 [CI 95% 
(2.241-11.392); p < 0.001]. TNF- immunoreactivity of 4.125 [CI 95% (1.805-9.425); p 
< 0.001]; and iNOS immunoreactivity of  3.546  [CI 95% (1.613-7.795); p = 0.002]. 
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There were correlations between TNF- level, TNF- and iNOS immunoreactivity and 
VAS with coefficient correlation: 0.330; 0.285 and 0.275 (p < 0.05) respectively.  
It is concluded that Diabetic Neuropathy patients with high TNF- levels, iNOS 
and TNF- immunoreactivity of mononuclear cells have higher risk  for painful DN than 
painless DN. The higher TNF- level, iNOS and TNF- immunoreactivity the more 
severe was the pain. This supports the hypothesis that TNF- and iNOS have role in 
PDN pathogenesis. The results of this research could be applied as a basic for further 
research in pursuit of better management of PDN. 
 
Keywords: Painful Diabetic Neuropathy; TNF-;  iNOS, Visual Analog Scale 
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1. Introduction 
The Indonesian Diabetes Federation (Perkeni) has published new data indicating the 
enormity of the diabetes epidemic. Urbanization and changing of life style may account 
for this problem. About 14.7% prevalence of diabetes is in urban area and 7% is in rural 
area, in 2003 an estimated 8.2 million in urban and 5.5 million persons in rural area had 
diabetes (Perkeni, 2006). Uncontrolled diabetes potentially suffered from acute and 
chronic complications, disability, and death. The most common chronic complications of 
diabetes are dyslipidemia (67.0%), symptomatic diabetic neuropathy (51.4%) and erectile 
dysfunction/impotence (50.9%) (Tjokroprawiro, 1993). Diabetic neuropathy is a common 
complication of diabetes that can cause significant morbidity and mortality. Some 30% of 
hospitalized and 20% of community-dwelling diabetic patients has peripheral 
neuropathy; the annual incidence rate is approximately 2% (Duby et al, 2004). 
Diabetic neuropathy (DN) can be painful or painless. The reason for this difference in 
clinical presentation is as yet unknown. The prevalence of painful diabetic neuropathy 
(PDN) in a population-based sample is 26.4 % (Davies, et al. 2006). PDN is difficult to 
treat as it does not respond to conventional analgesics. PDN can have a serious impact on 
quality of life, leading to severe depression and even suicide. Clinical manifestation of 
PDN may include burning, shooting (like ‘electric shock’ down the legs), lancinating 
(stabbing or knife like) and deep aching quality, allodynia and hyperalgesia especially in 
lower extremities (Benbow et al., 1998; Backonya, 2001; Meliala, 2004a). The 
pathogenesis of PDN is complex and still poorly understood. In the past, researches of 
neuropathic pain were focused on neuron and neurotransmitters so the treatment of 
neuropathic pain often unsatisfactory. Recently it has become clear that nitric oxide (NO) 
and proinflammatory cytokines play an important role in the pathogenesis and 
maintenance of pain in PDN. Neuroinflammation and neuroimmune activation occur 
following injury to peripheral nerves and nerve roots as well as in peripheral 
inflammatory models of persistent pain (Moalem et al., 2005; Koch, et al., 2007). The 
role of cytokine in the induction and maintenance of pain has been established in animal 
model, clinical research also gives evidence for the involvement of cytokine in painful 
and painless neuropathies (Sommer & Schafers, 2004). Peripheral nerve injury induces 
activation of resident immune cells as well as recruitment of inflammatory cells to the 
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nerve. Injury of a peripheral nerve initiates an inflammatory cascade in which mast cells 
residing in the nerve are the first to be activated. A variety of immune mediators are 
released, which exert algesic actions by acting directly on nociceptors, or indirectly via 
the release of other mediators. There is increasing knowledge of the intracellular cascades 
that are activated in nociceptors by some mediators Tumor Necrosis Factor (TNF)-α, 
Interleukin-1β, Interleukin-6; NO, prostaglandins (PG), nerve growth factor (NGF), 
cyclooxygenase 2, which ultimately either activate or sensitize these neurons. Nerve 
injury also initiates Schwann cell de-differentiation and the release of several algesic 
mediators such as pro-inflammatory cytokines, NGF, PGE2 and ATP. This cocktail of 
mediators serves as a mechanism of enhanced inflammatory response in the injured nerve 
and contributes to neuropathic pain (Moalem & Tracey, 2005; Thacker et al., 2007). 
TNF- α has been shown to be directly involved in the production of pain in several 
models of nerve injury. Injury-induced increases in TNF-α mRNA and protein expression 
have been observed to correlate with the development of allodynia/hyperalgesia in 
several neuropathic pain models. The effect of TNF-α on neurons seems to be mediated, 
directly and/or indirectly, by the phosphorylation of extracellular regulated kinase and 
p38 mitogen activated protein kinase (Schafers et al.,2003), translocation of NFκB to the 
nucleus and activation of COX-2-dependent prostanoid release (Dinarello, 1999). The 
phosphorylation of p38 mitogen activated protein kinase may mediate mechanical 
allodynia via a modulation of tetrodotoxin-resistant Na channels (Jin & Gerean, 2006). 
TNF-α also activates NFkB (Nuclear Factor kappa B) for initiation of NOS (Nitric Oxide 
Synthase) and NO production whereas NO is a pain neurotransmitter (Lowenstein, 1994).  
Previous data suggest that the clinical application of specific agents that suppress the 
production and/or activity of TNF-α may inhibit the development and exacerbation of 
chronic diabetic complications. Studies have revealed that an increased concentration of 
TNF-α correlates well with increased concentrations of NF-κB. Inhibition of serum TNF-
α and NO levels  with insulin and its combinations with resveratrol and curcumin 
contribute in attenuating diabetic neuropathic pain, since TNF-α plays an important role 
in the development of diabetic neuropathy (Sharma, et al., 2007). The role of NO in 
pathogenesis of PDN seems to be via up-regulation of iNOS as a result of chronic 
inflammation. There was reciprocal interactions between NO and PG, high levels NO 
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increased PDN and iNOS inhibitor attenuated PDN. With this background, the present 
study was designed to explore the plasma level of TNF-α and mononuclear cells iNOS 
and TNF-α expression as risk factors for PDN.  
 
2. Patients and Methods 
2.1  Study subjects 
A hundred and ten type-2 diabetic patients whom fulfilled inclusion criteria were enrolled 
in this study (61 women and 59 men, mean age 54.1, range 37-65 years). Patients were 
recruited consecutively at the outpatient Clinic of Neurology and Internal Medicine 
Sanglah Hospital Denpasar from 1 October 2008 until 31 July 2009. The patients had a 
means duration of diabetic 5.30  years (2-10 years). Of 110 subjects, 59 patients suffered 
from Painful DN (case) and the remain 51 patients were Painless DN (control). The 
clinical characteristic of  subjects and comparison of case and control group are given in 
Table 1 and 2 . 
2.2  Inclusion criteria 
Cross sectional study : type-2 diabetic patients, age between 20-65 years, duration of  
diabetes 2-10 years  since diagnosis established, patients live in Bali, signed written 
informed consent. Case control study: same with cross sectional study criteria plus 
Painless DN for control and Painful DN for case. 
2.3  Exclusion criteria 
Exclusion criteria included : ongoing local and systemic infection ( documented with a 
blood cell count and erythrocyte sedimen rate ), active ulcer in the leg, patients under 
treatment of glyceryl trinitrate  or  sildenafil , herbal or synthetic medication that contain 
anti oxidant or anti inflammation  and patients suffering another neuropathic pain.  
To minimize confounding factors for blood cytokine levels, the study conditions were 
standardized by applying the following exclusion criteria: heavy physical activity in the 
last 3 days, food intake within 60 minutes before blood sampling, alcohol consumption 
up to 24 hours before the examination, and any current infectious disease or fever. 
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2.4 Method 
2.4.1  Study protocol 
The study was carried in two step. The first step was a cross sectional and the second step 
was a case-control study. In cross sectional study, type-2 diabetic patients who visited 
outpatients Neurology and Internal Medicine Clinic Sanglah Hospital were performed 
anamnesis, neurological, laboratory and ENMG ( Electromyoneurography). The 
diagnosis of a DN was based on a typical history and a thorough neurologic and ENMG 
examination . Laboratory studies included erythrocyte sedimentation rate, whole blood, 
blood sugar, HbA1C, ureum, creatinin and liver function test. A complete 
electrophysiologic assessment with standard nerve conduction studies in motor and 
sensory nerves at upper and lower extremities  was performed in all diabetic patients. 
Nerve conduction studies revealing low compound muscle action potentials and sensory 
nerve action potentials or low conduction velocities.  
Patients who  diagnosed  DN and  fulfilled inclusion criteria were recruited in case-
control study and were asked to assess their pain intensity on visual analog scale (VAS), 
with 0 representing no pain and 10 representing the worst pain imaginable.  Patients were  
attributed to two  groups according to their VAS: 1–5 mild pain and 6–10 severe pain. 
Patients also examined blood test for plasma TNF-α level  by ELISA and iNOS and TNF-
α expression in mononuclear cells immunohistochemically. 
 
2.4.2 ELISA 
Blood for TNF-α analysis  was drawn in the morning, stored at 4° C, centrifuged at 1500 
rpm  for 10 minutes and the plasma was stored at – 20 ° C  until assayed. The presence of 
TNF-α in plasma was detected by commercially available ELISA Kit (R&D system, 
Wiesbaden, Germany).  
 
2.4.3 Immunohistochemistry 
Detection TNF and iNOS expresson in mononuclear cells  
Approximately 3 ml blood was collected from DN patients. The blood was centrifuged at 
1500 rpm for 10 minutes and the plasma was collected into small aliquots. Buffy coat 
layer at the interface was collected into a clean centrifuge tube. Red blood cells present in 
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the buffy coat were lyzed using 0.8 % NH4Cl for 1 minute and leucocytes were pelleted 
by centrifugation as above. Leucocytes were washed twice by repeated centrifugation and 
a thin smear of leucoytes at the density of 1 million per 1 ml PBS was prepared on poly-
L-lysine microscope slides. After air dried, the leucocytes were fixed with cold acetone 
for 20 minutes.The endogenous peroxidase of the leucocytes was then inactivated by 3% 
H2O2 in PBS for 30 minutes at room temperature. After blocking with 2% skim milk in 
PBS, monoclonal antibodies (MAb against TNF- (biodesign international) and against 
iNOS (Santa Cruz biotechnology) was added into leucocytes smear on microscope slides. 
After three time washes with PBS (pH. 7.4) and incubated for 1 hour at room 
temperature. The bound mAbs were the detected by biotinylated goat anti-mouse IgG 
(Biodesign International) and avidin-horse radish peroxidase (Sigma Co, USA). The 
expression of TNF- and iNOS were then visualized by adding Diazinobenzidine (DAB) 
substrates (Sigma Co, USA, 50 mg/50 ml PBS containing 0.07% H2O2). The 
mononuclear  cells   expressed   iNOS and TNF-α were count  under 450 x manigtude 
microscope  by observation of 100 cells. 
 
2.4.4  Cut off point 
Cut off point for risk factors plasma TNF- levels, iNOS and TNF- expression in 
mononuclear cells are median of  the risk factors respectively. Cut of point of HbA1C is 
7 %. 
  
2.4.5  Statistical analysis 
Data obtained from this study comprised descriptive analysis, non parametric One sample 
Kolmogorov-Smirnov test, bivariate correlation test, stepwise linear regression test, cross 
tab ( chi-square test and odds ratio) and logistic regression test. The data were  analyzed 
using SPSS software, version 15 with significant values p < 0.05. 
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Table 1  Characteristic of  Diabetic Neuropathy Patients 
 
Variable                                     N Range Mean ± SD
Age ( years )                               110 37-65 54,11 ± 7,64
Gender   
 Women  61  
 Men 49  
Duration of DM (years) 110 2-10 5,30 ±  3,05
PDN   
 Yes 59  
 No 51  
Fasting Blood sugar (mg %)      110 65 - 363            167  ±   70
Blood sugar 2 hourspp (mg%)   110 102 - 588             255  ±  105
HbA1C  (%)                             110 3,30  - 18,60        9,69  ± 3,49
Plasma TNF-α  (pg/ml)              110 5,40 - 56,64   15,06  ± 7,01
TNF-α  expressión (%)              110 0 – 40 12,43 ± 10,36
iNOS    expressión  (%)             110 0 – 38   9,22 ± 9,33
 
SD  = standard deviation ;  N =  total sample;  TNF = Tumor Necrosis Factor .  
iNOS = inducible Nitric Oxide Synthase ; HbA1C = Glycosylated Hemoglobine 
 
 
Table 2. Comparison Clinical Data of Painful DN ( Case ) and Painless DN (Control) 
 
Characteristic Case 
Mean ± SD         
Control  
Mean ± SD           
        P 
Age  (years)                                 53,97 ±   8,26       54,27 ±  6,94         0,834
Duration of Diabetes  (years)     5,31   ±   3,13       5,29 ±  2,99 0,985
Fasting Blood Sugar ( mg %)    168,96 ± 73,02      165,31 ± 69,14        0,789
Blood Sugar 2hourspp (mg %) 259,37 ± 109,51     251,96 ± 100,77       0,714
Hb A1C ( % )                             10,40 ± 3,61        8,88 ±  3,18          0.023
Plasma TNF-α   ( pg/ml)    17,44 ± 8,23        12,30 ±  3,76 < 0,001
iNOS    expression (%)              12,21 ± 10,43       5,77 ±  6,41          < 0,001
TNF-α  expression  (%)             16,15 ± 11,05      8,13  ± 7,56          < 0,001
 
TNF = Tumor Necrosis Factor ; SD = standard deviation;  p = significant level. 
iNOS = inducible Nitric Oxide Synthase;     HbA1C = Glycosylated Hemoglobine 
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3. RESULT 
3.1 Characteristic of  mononuclear cells that expressed TNF-α dan iNOS  
  The mononuclear cells expressed  TNF-α and iNOS are characterized by 
brownish cytoplasma and violet-blue of nucleus as depicted in Figure 1 and 2. 
 
 
 
Fig 1. Expression of TNF-α in mononuclear cells 
 
 
.  
 
Fig.2. iNOS expression in mononuclear cells 
 
 
3.2 Cross sectional Study 
3.2.1 Comparison of  risk factors of PDN according pain intensity 
Of 110 subjects, 59 patients suffered from Painful DN which consist of 34 mild pain and 
25 severe pain. Plasma TNF- levels,  iNOS and TNF- expression  were higher in 
patients with more severe pain in the VAS  ( p < 0.05 ) as shown  in Figure 3.  
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Figure 3 
Plasma TNF- level, TNF- and  iNOS expression in mononuclear cells 
according to pain intensity. 
 
Plasma TNF- level, TNF- and iNOS expression of severe pain intensity were 
statistically significant higher than mild pain intensity patients ( means  20.44 ± 10.34 
pg/ml vs 15.24 ± 5.42 pg/ml ; 20.44 ± 11.75 % vs  13.00 ± 9.48 %  and 15.60 ± 11.84 %  
vs 9.72 ± 8.61% ; p < 0.05 ).  
 
3.2.2  Correlation between pain intensity and some risk factors of PDN 
Correlation between pain intensity and some risk factors PDN as age, duration of 
diabetes, blood sugar level, HbA1C, plasma TNF- level, TNF- and iNOS expression 
are given in Table 3. 
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Table 3. Correlation between pain intensity and some risk factors of PDN 
 
 Pain intensity  
Variable  R p 
Age -0,144 0,275 
Duration of Diabetes -0,101 0,448 
Fasting blood sugar darah  0,196 0,136 
Blood sugar 2 hours post prandial   0,177 0,180 
Hb A1C 0,138 0,298 
Plasma TNF-α 0,330 0,011*
iNOS Expression 0,285 0,029*
TNF-α expression  0,275 0,035*
 
TNF = Tumor Necrosis Factor ;      HbA1C  = Glycosylated Hemoglobine 
iNOS = inducible Nitric Oxide Synthase ;   r = coefficient correlation 
p = significant level;     * statistical significant 
 
Correlation between pain intensity and age, duration of diabetes, fasting blood sugar, 
blood sugar 2 hpp and  HbA1C were not statistically significant ( p > 0.05) where as 
correlation between pain intensity and plasma TNF- level, TNF- and iNOS expression 
are statistically significant with r = 0.330 , 0.285 and 0.275  ( p < 0.05). 
To investigated correlation between  plasma TNF-α,  iNOS dan TNF-α expression in 
mononuclear cells as risk factors of PDN , a bivariat correlation test was conducted . 
There were positive correlation between 3 risk factors above that  statistically significant. 
( p < 0,05 ). Correlation between plasma  TNF-α and iNOS expression was moderate  ( r 
= 0,348) , correlation between plasma TNF-α and  TNF-α expression also moderate ( r = 
0,389), where as correlation between  TNF-α and  iNOS expression was strong ( r = 
0,705 ). Linear regression test showed that those 3 risk factors of PDN altogether have 
effect on pain intensity by 22.6 %, ( p < 0.05 ) while their individual effect was not 
statistically significant.  
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3.3 Case control study  
3.3.1 Risk of high plasma TNF-α  level to PDN event 
 The odds ratio of  high plasma TNF-α  level to PDN event were 5.053, 
Confidence Interval (CI) 95% ( 2.241-11.392),  it indicated that DN patients with high  
plasma TNF-α  level  had risk 5.053 times higher of getting PDN than low plasma TNF-α  
level ( p < 0.001 ).  
 
3.3.2 Risk  of high TNF-α  expression  in mononuclear cells  to PDN event 
The odds ratio of  high TNF-α  expression to PDN event were 4.125, Confidence Interval 
(CI) 95% ( 1.805-9.425),  it indicated that DN patients with high  TNF-α expression  had 
risk 4.125 times higher of getting PDN than low  TNF-α expression.( p < 0.001). 
  
3.3.3 Risk  of high iNOS  expression  in mononuclear cells  to PDN event 
The odds ratio of  high iNOS  expression to PDN event were 3.546, Confidence Interval 
(CI) 95% ( 1.613-7.795),  it indicated that DN patients with high iNOS expression  had 
risk 3.546 times higher of getting PDN than low  TNF-α expression.( p < 0.002) 
 
3.3.4 Risk  of high  HbA1C level  to PDN event 
The odds ratio of  high level HbA1C to PDN event were 2.380, Confidence Interval (CI) 
95% ( 0.996-5.688) and p > 0.05.  it indicated that high HbA1C level  were not increasing 
risk of getting PDN than low plasma HbA1C  level. 
 
3.3.5 The role of risk factors to PDN event 
To investigate the role of some risk factors which categorically have significant odds 
ratio to PDN event, such as plasma TNF- levels, iNOS and TNF- expression; a 
forward stepwise (conditional) logistic regression test was conducted. All of 3 risk factors 
above had a role to PDN event. The odds ratio of plasma TNF-α ,  iNOS and TNF-α  
expression were : 5.053  and 3.735  ( p < 0.05 ) ( Table 4) 
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 Table 4. The role of  plasmaTNF-α , iNOS and  TNF-α expression to PDN event 
Variable   B Exp(B) 95% CI P 
1.Plasma TNF-α 1,620 5,053 2,241 - 11,392  < 0,001* 
2.TNF-α expression 1,318 3,735   1,587 -   8,,787     0,003 * 
B = beta ; CI = Confidence interval ;  * statistically significant. 
 
3.4 Summary of Study Result 
In overall, the study result could be summarized as follow : cross sectionally the higher 
plasma TNF- level, iNOS and TNF- expression in mononuclear cells the more severe 
was the pain. There were positive correlation between pain intensity and plasma TNF- 
level, iNOS and TNF- expression, also moderate to strong correlation each other 
between 3 risk factors above.  
In case-control study : plasma TNF-α as a risk factor was consistently and to be the most 
important risk factor of  PDN, both direct and indirect by increasing expression of TNF-α 
and iNOS. TNF-α expresión appeared to be the second most important risk factor after 
plasma TNF-α and  also both direct and indirect increasing the risk of PDN via plasma 
TNF- level and iNOS  expression.  
  
4.Discussion 
4.1 Diabetic Neuropathy as chronic complication of diabetes 
In this study of 110 subjects whom fulfilled cross sectional inclusion criteria all subjects 
also fulfilled inclusion criteria for case control study, 59 subjects suffered from Painful 
DN and 51 subjects suffered from Painless DN. All diabetic patients who have been 
suffering diabetes for 2 years or more in this study suffered DN, this finding supported 
the reference that DN as complication of diabetes has already present early stage of 
hyperglycemia process before clinical diagnosis ( Soliman, 2004) 
 
4.2 . Comparison of  risk factors of PDN according pain intensity 
Comparison of  plasma TNF-α and expression of  iNOS and TNF-α according pain 
intensity were depicted in Fig. 3. There were tendency the higher plasma TNF- level, 
iNOS and TNF- expression in mononuclear cells the more severe was the pain, this 
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differences statistically significant ( p < 0.05 ). These results are in agreement with 
previous study of cytokine expression in  nerve Suralis biopsy specimen of   neuropathy 
patients.  Patients with painful neuropathies showed a stronger TNF-α immunoreactivity 
compared with patients with nonpainful neuropathy (0.949 ± 0.047 vs 1.010 ± 0.053, p < 
0.05).(Empl et al.,2001). Study Uceiler et al. (2007) reported  patients with a painful 
neuropathy had about twofold higher TNF-α mRNA (p < 0.0001) and protein levels (p = 
0.009) than healthy control subjects and about twofold higher IL-2 and TNF mRNA (p = 
0.03; p = 0.001) and protein levels (p = 0.04 ) than patients with painless neuropathy. 
Our study showed plasma TNF- α level in PDN had nearly 1.5 fold higher than Painless 
DN (17.44 ± 8.23 pg/ml  vs  12.30 pg/ml ± 3.76 pg/ml, p < 0.001) and TNF-α expression 
in PDN had nearly twofold higher than Painless DN (16.15 ± 11.05 vs  8.13 ± 7.56 % , p 
< 0.001). Doganay et al.(2002) investigated relation between the stages of DR ( Diabetic 
Retinopathy) highest values obtained in patients with PDR ( Proliferative Diabetic 
Retinopathy). Taken together, the mean serum NO, sIL-2R, IL-8 and TNF-α  levels 
increased with the stage of DR and the highest levels were found in patients with PDR. In 
our study the highest levels of  TNF-α ( 56.64 pg/ml ) and iNOS ( 38% ) and TNF-α 
expression ( 40% ) also were found in patients with PDN. Pro-inflammatory cytokines 
(IL-1β, IL-2, IL-6, IFN-γ, TNF-α) in the plasma correlate with increasing pain intensity. 
Chronic pain patients show a significant increase in plasma levels of NO in comparison 
to healthy controls.( Koch et al.,2007). Another study also showed correlation between 
pro inflammatory cytokine and pain intensity or severity of the disease in Juvenile 
rheumatoid arthritis ( Chen  et al., 2004) and fibromyalgia ( Gur et al., 2002 ). 
 
4.3 Correlation between pain intensity and some risk factors of PDN 
There were positive correlation between pain intensity and plasma TNF- level, iNOS 
and TNF- expression, also moderate to strong correlation each other between 3 risk 
factors above. Linear regression test showed that those 3 risk factors of PDN altogether 
have effect on pain intensity by 21.5%, ( p < 0.05 ) while their individual effect was not 
statistically significant. The contributed of plasma TNF- level, iNOS and TNF- 
expression in pathogenesis PDN were 21.5 % beside this there were still 78.5% another 
factors  play a role in pathogenesis PDN. 
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Correlation between pain intensity and age, duration of diabetes, fasting blood sugar, 
blood sugar 2 hpp and  HbA1C were not statistically significant ( p > 0.05), it indicated 
that  factors above were not proven increased PDN event.  
 
4.4. Odds ratio of risk factors to PDN event 
Chi-square test revealed odds ratio of  high plasma TNF-α ,  high TNF-α  expression to 
OR high of iNOS expression to PDN were 5.053, 4.125 and 3.546, p < 0.001 
respectively. Forward stepwise (conditional) logistic regression test showed all of 3 risk 
factors above had a role to PDN event. The odds ratio of plasma TNF-α ,  iNOS and 
TNF-α  expression were : 5.053, 2,869 and 4.327 , p < 0.05  respectively  ( Table 4). In 
contrast odds ratio of  high level HbA1C to PDN event were 2.380 , p > 0.05.  it indicated 
that high HbA1C level  were not increasing risk of getting PDN than low plasma HbA1C  
level. 
 
4.5 Summary of PDN Pathophysiology 
 
According to this research and supported by some other investigations, a 
pathophysiological relationship can be made between TNF-α, iNOS and PDN as depicted 
in figure 2 
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Figure 4 
Pathophysiological relationship between TNF-α, iNOS and PDN 
 
Prolong hyperglycemia in diabetic patients can causes diabetic pain through many 
mechanisms, including metabolic, oxidative stress, immunologic, AGEs, and vascular. 
All of those mechanisms relate closely with decreased eNOS which is followed by 
decrease in NO as eNOS is one of isoenzyme forming NO. NO are needed for 
vasodilating, inhibiting platelet aggregation and proliferation of smooth muscle (De 
Catarina et al., 1995). Decrease in NO will result in vessel endothelium disruption 
followed with nerve fiber disruption.    
Dysfunction or lesion in peripheral nerve fiber leads to membrane remodelling 
and hyperexcitability which in turn cause diabetic pain. Lesion in primary afferent nerve 
fiber will induce activation of immune resident cell and recruitment of inflammatory cells 
to the inflamed cell. Then inflammation cascade takes place as activated mast cells 
release TNF-α which sensitizes nociceptor and contribute to neutrophils and 
macrophages recruitment. In nerve cells, neutrophils and macrophages produce and 
secrete neurotransmitter, neuropeptide and inflammatory mediators such as TNF-α, 
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Prostaglandin E2 (PGE2), bradykinin, serotonin, histamine and NGF. Those cocktail 
mediators activate nociceptor directly, cause sensitization and contribute to neuropathic 
pain, which result in pain, spontaneously or primary hyperalgesia (Moalem & Tracey, 
2006). 
NO role is thought to be through increased iNOS following chronic inflammation 
in diabetic pain. Strong evidences support a reciprocal relationship between NO and PGs 
biosynthetic pathways (Mollace et al., 2005). NO and PGs interaction occurs in some 
levels. NO directly influences COX expression and PGs biosynthesis. Conversely, AA 
and its metabolites, which produced by COX isoform, are also have effect on NO 
biosynthesis. NO ability to directly activate COX-2 is supported by evidences that NO 
increases purified COX-2 recombinant enzymes. NO is also influential to COX-2 
enzymes activities by post transcription and translation process which make macrophages 
increase their PGs production. There are evidences that NO also activate COX-2 
(Mollace et al., 2005). NO release by cNOS in basal condition deactivates iNOS by 
inhibition of NFkB signal. NFkB signal is one of the signaling pathways for iNOS 
expression by means of extracellular mediators, including TNF-α (proinflammatory 
cytokine) and endotoxin (Chao et al., 1997). In low concentration NO, NFkB is 
maintained inactive (Togashi et al., 1997), while in high concentration NO, NFkB is not 
suppressed by NO so that it activates iNOS by producing combination anion superoxide 
from peroxynitrite . NFkB is a strong COX-2 inducer and inhibitory role of NO in COX-
2 is mediated by NFkB inhibition. This mechanism seems to be the basic NO inhibitory 
effect in PG biosynthesis (Mollace et al., 2005). Physiologically, iNOS is not expressed 
constitutively on mammal cells. Its expression is induced by proinflammatory agents 
such as bacteria LPS or cytokines. NO is produced by many type of cells in peripheral 
tissues after inflammation occurred. Once expressed, iNOS will produce NO in a large 
amount for a long period (Nathan, 1992).  
The finding of our study support Law of Pain hypotheses from Omoigui (2007) 
which states that every process of pain derived from inflammation and its responses. 
High NO is related with PDN while iNOS inhibitor can decrease PDN symptoms (Meller 
et al., 1994; Alba et al., 2006; Sharma et al., 2007). Evidence  that TNF-α and iNOS have 
important roles in pathogenesis PDN can lead to a new therapy strategy, that is by 
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modulating NO pathway and neuroimmune system. Modulation can be achieved by 
specifically inhibiting iNOS, antibody cytokine receptors and TNF-α. 
 
4.6 Novelty 
Plasma TNF-α level, iNOS and TNF-α expression in mononuclear cells have role in PDN 
pathogenesis. There is a spesific correlation between iNOS and TNF-α expression in 
mononuclear cells, in which both are thought to have important roles in PDN 
pathophysiology.  
 
4.7.Conclusion 
Diabetic Neuropathy patients with high TNF- levels, iNOS and TNF- 
immunoreactivity of mononuclear cells have higher risk for painful DN than painless 
DN. The higher TNF- level, iNOS and TNF- immunoreactivity the more severe was 
the pain. This supports the hypothesis that TNF- and iNOS have role in PDN 
pathogenesis. The results of this research could be applied as a basic for further research 
in pursuit of better management of PDN. 
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